NCLT meeting approves Chemgenix-Vilin amalgamation scheme
VILINBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
By the next day the stock moved 0.7 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vilin Bio Med submitted the Scrutinizer's Report for the NCLT-convened meeting held on Oct 15, 2026. Equity shareholders approved the Scheme of Amalgamation of Chemgenix Laboratories Pvt Ltd into Vilin Bio Med unanimously: 24,83,085 votes (100%) in favour, none against, representing 16.28% of paid-up equity. Unsecured creditors also approved, with Evexia Lifecare (holding 92.21% of unsecured debt) voting in favour. The scheme now awaits NCLT sanction.
Positive procedural step for the merger; pending NCLT sanction before scheme becomes effective.